Stroke, Ischemic
Conditions
Keywords
Selective Serotonin Reuptake Inhibitor, Neuroplasticity, Paired Associative Stimulation
Brief summary
The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke.
Detailed description
The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke. Selective serotonin reuptake inhibitors (SSRIs) are currently widely used for treatment of depression, but they also have been shown to be able to enhance neuroplasticity. A single dose of SSRI has been shown to improve hand function in patients with chronic stroke. SSRIs also enhance neuroplasticity in healthy individuals, as shown using paired associative stimulation (PAS), a non-invasive method which causes the brain's excitability to change. However, the best dose of SSRI to increase neuroplasticity is not yet established. The purpose of this study is to (1) find the effective dose of the SSRI escitalopram to modulate PAS-induced plasticity in patients with stroke and healthy individuals and (2) determine the variability of escitalopram's effect on PAS-induced plasticity between individuals. We measure neuroplasticity with PAS, which causes the brain's excitability to change. During PAS, you would receive electrical stimulation over your wrist and magnetic stimulation to their scalp (called transcranial magnetic stimulation, or TMS) to increase the excitability of the motor area of the brain. You will be asked to participate in a screening visit and 8 study visits separated by at least 1 week. At each study visit, you will be given a single dose of escitalopram (5, 10 or 20) or placebo, and we will measure your brain's change in excitability after PAS.
Interventions
DRUGAdministration of SSRI escitalopram
Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
BEHAVIORALPaired Associative stimulation
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
Participants will be administered a placebo prior to paired associative stimulation
Sponsors
Burke Medical Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
We propose a double-blinded, placebo-controlled crossover study to test a range of doses of escitalopram and a placebo control in enhancing PAS-induced plasticity in healthy individuals without neurological disease and patients with chronic stroke.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Neurological Healthy Participants Inclusion criteria 1. Men and women aged 18 years and older. 2. Ability to give informed consent.
Exclusion criteria
1. Contraindications to TMS: epilepsy or other seizure history, ferromagnetic metallic implants in the head, or pacemaker 2. Current or history of neurological disorders or brain lesions such as stroke, multiple sclerosis, tumor, traumatic brain injury, spinal cord injury 3. Diagnosis of major depressive disorder or other psychiatric disorder 4. Currently taking escitalopram or another selective serotonin reuptake inhibitor 5. Currently taking or have taken in the past month other medications or supplements that have known interactions with escitalopram or can precipitate serotonin syndrome when taken in combination with escitalopram: monoamine oxidase inhibitors, methylene blue, linezolid, serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort 6. Known hypersensitivity to escitalopram or any of its inactive ingredients. 7. History of cerebral hemorrhage, gastrointestinal bleeding, or genitourinary bleeding. 8. History of prolonged QTc 9. Pregnant or breastfeeding 10. Social and/or personal circumstances that interfere with the ability to return for all study visits. Stroke Patients Inclusion criteria 1. Men and women aged 18 years and older. 2. Ability to give informed consent. 3. History of ischemic stroke
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in motor evoked potential amplitude | Baseline, Up to 30 minutes Post PAS | Assessment of corticospinal excitability |
Countries
United States
Outcome results
None listed